MAXON/PIXOLOGIC
11.1.2022 19:42:13 CET | Business Wire | Press release
Maxon, developer of professional 3D software solutions, is pleased to announce the completion of all financial and regulatory requirements for the acquisition of all assets of Pixologic, creators of the Academy Award-winning ZBrush sculpting and painting software. As an added benefit, the entire ZBrush team has already joined Maxon, bringing decades of 3D industry expertise. The move suitably rounds out Maxon’s product line and firmly positions the company as an industry leader for providing superior creative tools to digital artists to the €16 billion 3D Animation Industry.*
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110006049/en/
No interruptions are expected for the ongoing development of ZBrush post-acquisition. Nevertheless, the collaboration with Maxon’s development team, access to its other technologies and the potential integrations therein are expected to bring greater innovation and expanded capabilities to ZBrush and the entire Maxon product line. Additionally, the inclusion of the ZBrush team assures greater marketing, training and support resources.
“We are excited to start working with the Maxon team,” said Ofer Alon, Founder and Visionary of Pixologic. “Our synergies are undeniable - both companies share a great tradition of outstanding products, innovation and a passion to serve the creative community.”
“I’m excited to see how this alliance will influence, evolve and enrich all our product offerings,” stated David McGavran, Maxon CEO. “We have our eyes towards not only transforming creative workflows; we’re aspiring to revolutionize the industry.”
Immediate Impact: Pricing and Availability
Until further notice, ZBrush pricing remains unchanged following the completion of the acquisition. Customers can continue to purchase ZBrush through their usual sales channels, including the ZBrush online store.
Please refer to the FAQ for additional information.
*Research and Markets, Global 3D Animation Market Size, Share & Trends Analysis Report by Technique (3D Modeling, Visual Effects), by Component, by Deployment (On-premise, On-demand), by End Use, and Segment Forecasts, 2021-2028, June 2021 - More Info
About ZBrush
ZBrush is used by respected film studios, game developers, designers, advertisers, illustrators, and scientists around the world. The industry’s top creatives have employed ZBrush for nearly every major franchise including Dune, Star Wars, Avatar, the Marvel Cinematic Universe, Game of Thrones, Lord of the Rings/The Hobbit and more. Its versatility has also made it an integral part of animated features such as Frozen, Moana, Raya and the Last Dragon, and Encanto. ZBrush has also been used extensively in Triple A games including Fortnite, the God of War franchise, Uncharted franchise, Assassin's Creed franchise, Far Cry franchise
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110006049/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom